IFNA1 and myeloid sarcoma: Further studies to unravel the detailed molecular mechanisms underlying the altered IFNAR2 protein levels and signalling in carriers of the MS-protective class I alleles are warranted as this may identify novel therapeutic targets to reduce the I IFN signalling specifically in B cells and T cells.